I have committed today at 1.7p, my first investment ever in anything outside the FT250. From my understanding of this sector, I don't expect much movement either up or down for a while. Let's hope that my last "one and only" Cheltenham Gold Cup 1990 ..Nortons Coin 100:1 outsider is replicated here. I'm not holding my breath, nevertheless I have a feeling that this one is also worth a punt.
A nice rise for the last few days as the volume has been rising from the first day.
The chart just look bullish as the 2 weeks flat bottom is now rising on the right side, catching up an closing the GAP
Yesterdays announcement should mean good times ahead? . does pharmaspecialist have an opinion? not sure how long something like this would take to get to market but seeing as it is an adaptation of an existing drug, rather than a new one, this would mean no lengthy FDA approvals etc?. I am not an expert in this field so anyone's input would be appreciated.
I am amazed at the lack of information about the company's formulation technology on the web site as this is critical to the company's success. Unless I have missed something, there does not seem to be much scientic validation of this technology either, where did it originate? Even the 2014 annual report is a bit sketchy about the technology. Biotech companies normally like to publicise their technologies and if they are any good, they would normally be patented so no risk from competitors. If I were an investor I would also be concerned about the July 31 press release saying that the pilot clinical study of OXPzero Naproxen produced "encouraging results". The results were not encouraging because there was no evidence that the OXPzero drug reduced gastrointestinal irritation and the reduction in the number of erosions was not statistically significant, in fact I would say that this study raises questions over whether the company's formulation technology (whatever it is) works. I hope Mr. Woodford got a biotech specialist to do due diligence on this company before he invested!
My analysis is that it has already taken its beating, at 13.5p the shares high, it had come down to 9p nearly a 33% decline which shows that the market had already factored in the poor results coming out on Friday however there is still some more news about to come out which I think will be good news which everyone is a lot more confident about which will see this at about 12p or more depending how well the results are, let's see, we have had a big companies support this share at 10p, those decisions are not made lightly and I think the results were already known at that point.
Important message from the Financial Conduct Authority:
Posting inside information that is not public knowledge, or information that is false or misleading, may constitute market abuse.
This could lead to an unlimited fine and up to seven years in prison.
If you have any information, concerns or queries about market abuse, click here.
The content of the messages posted represents the opinions of the author, and does not represent the opinions of Interactive Investor Trading Limited or its affiliates and has not been approved or issued by Interactive Investor Trading Limited.
You should be aware that the other participants of the above discussion group are strangers to you and may make statements which may be misleading, deceptive or wrong.
Please remember that the value of investments or income from them may go down as well as up and that the past performance of an investment is not a guide to its performance in the future.
The discussion boards on this site are intended to be an information sharing forum and is not intended to address your particular requirements.
Whilst information provided on them can help with your investment research you need to consider carefully whether you should make (or refraining from making) investment or other decisions based on what you see without doing further research on investments you are interested in.
Participating in this forum cannot be a substitute for obtaining advice from an appropriate expert independent adviser who takes into account your circumstances and specific investment needs in selected investments that are appropriate for you.